# EDGAR Filing Document

**Accession Number:** 0001621443
**File Stem:** 0001104659-23-037414
**Filing Date:** 2023-3
**Character Count:** 19055
**Document Hash:** 2922b76304c8034482babe80f66d120a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-037414.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001104659-23-037414

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**EFFECTIVENESS DATE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zynerba Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001621443
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 260389433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270891
- **FILM NUMBER:** 23766276

**BUSINESS ADDRESS:**
- **STREET 1:** 80 W. LANCASTER AVENUE
- **STREET 2:** SUITE 300
- **CITY:** DEVON
- **STATE:** PA
- **ZIP:** 19333
- **BUSINESS PHONE:** 484-581-7505

**MAIL ADDRESS:**
- **STREET 1:** 80 W. LANCASTER AVENUE
- **STREET 2:** SUITE 300
- **CITY:** DEVON
- **STATE:** PA
- **ZIP:** 19333

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zynerba Pharmeceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141003

**As filed with the Securities and Exchange Commission on March 28** **, 2023**

**Registration No. 333-**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION** **<br> Washington, D.C. 20549**

**FORM S-8**<br> **Registration statement<br> under<br> the securities act of 1933**

<br> **Zynerba Pharmaceuticals, Inc.**<br> **(**Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **26-0389433** |
| (State or other jurisdiction of incorporation or<br> organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **80 W. Lancaster Avenue, Suite 300**<br> **Devon, PA**<br> (Address of Principal Executive Offices) | **19333**<br> (Zip Code) |

---

**ZYNERBA PHARMACEUTICALS, INC.<br> AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE COMPENSATION PLAN**<br> (Full title of the plan)

**Armando Anido<br> Chairman and Chief Executive Officer<br> Zynerba Pharmaceuticals, Inc.<br> 80 W. Lancaster Avenue, Suite 300<br> Devon, PA 19333**<br> (Name and address of agent for service)<br> **(484) 581-7505**<br> (Telephone number, including area code, of agent for service)<br>

**with a copy to:**

**Rachael M. Bushey, Esq.<br> Jennifer L. Porter, Esq.**<br> Goodwin Procter LLP<br> 2929 Arch Street, Suite 1700<br> Philadelphia, PA 19104<br> (445) 207-7805<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement is being filed for the purpose of registering an additional 1,500,000 shares of common stock, $0.001 par value per share (the "Common Stock"), of Zynerba Pharmaceuticals, Inc. (the "Registrant") that were added to the shares authorized for issuance under the Zynerba Pharmaceuticals, Inc. Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the "Plan") for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective.

The Registrant previously filed the Registration Statements on Form S-8 (File Nos. [333-207973](https://www.sec.gov/Archives/edgar/data/1621443/000110465915078387/a15-20221_1s8.htm),[33-216968](https://www.sec.gov/Archives/edgar/data/1621443/000110465917019424/a17-9122_1s8.htm), [333-223597](https://www.sec.gov/Archives/edgar/data/1621443/000110465918016739/a18-7995_2s8.htm), [333-230182](https://www.sec.gov/Archives/edgar/data/1621443/000110465919013754/a19-6177_1s8.htm), [333-237051](https://www.sec.gov/Archives/edgar/data/1621443/000110465920031380/tm2011971-1_s8.htm),[333-256028](https://www.sec.gov/Archives/edgar/data/1621443/000110465921064891/tm2115829d1_s8.htm) and [333-263128](https://www.sec.gov/Archives/edgar/data/1621443/000110465922028332/tm227886d1_s8.htm)) with the Securities and Exchange Commission (the "Commission") to register 10,209,030 shares of Common Stock that were authorized for issuance under the Plan. Upon the effectiveness of this Registration Statement, an aggregate of 11,709,030 shares of Common Stock will be registered for issuance from time to time under the Plan. Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos. [333-207973](https://www.sec.gov/Archives/edgar/data/1621443/000110465915078387/a15-20221_1s8.htm), [333-216968](https://www.sec.gov/Archives/edgar/data/1621443/000110465917019424/a17-9122_1s8.htm), [333-223597](https://www.sec.gov/Archives/edgar/data/1621443/000110465918016739/a18-7995_2s8.htm), [333-230182](https://www.sec.gov/Archives/edgar/data/1621443/000110465919013754/a19-6177_1s8.htm), [333-237051](https://www.sec.gov/Archives/edgar/data/1621443/000110465920031380/tm2011971-1_s8.htm), [333-256028](https://www.sec.gov/Archives/edgar/data/1621443/000110465921064891/tm2115829d1_s8.htm) and [333-263128](https://www.sec.gov/Archives/edgar/data/1621443/000110465922028332/tm227886d1_s8.htm)) filed with the Commission on November 13, 2015, March 27, 2017, March 12, 2018, March 11, 2019, March 10, 2020, May 12, 2021 and March 1, 2022, are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

**PART ii**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[(a) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 28, 2023;](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001621443/000155837023004765/zyne-20221231x10k.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed on [January 9, 2023](https://www.sec.gov/ix?doc=/Archives/edgar/data/1621443/000110465923002058/tm232480d1_8k.htm) and [March 28, 2023](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001621443/000110465923037398/tm2310606d1_8k.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[(c) The description of the Registrant's Common Stock contained in the Form 8-A filed with the Commission on July 30, 2015 pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of further updating such description.](https://www.sec.gov/Archives/edgar/data/1621443/000110465915054702/a14-26946_78a12b.htm)

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

**Item 8 Exhibits.**

---

| | |
|:---|:---|
| Exhibit<br> No. | Description |
| [4.1](https://www.sec.gov/Archives/edgar/data/1621443/000104746915006747/a2225690zex-3_1.htm) | [Sixth Amended and Restated Certificate of Incorporation of Zynerba Pharmaceuticals, Inc., effective August 10, 2015 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37526) filed on August 10, 2015).](https://www.sec.gov/Archives/edgar/data/1621443/000104746915006747/a2225690zex-3_1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1621443/000155837021010876/zyne-20210630xex3d1.htm) | [Amended and Restated Bylaws of Zynerba Pharmaceuticals, Inc., effective July 29, 2021 (incorporated herein by reference to Exhibit 3.1 to the Registrant's Form 10-Q (File No. 001-37526) filed on August 9, 2021).](https://www.sec.gov/Archives/edgar/data/1621443/000155837021010876/zyne-20210630xex3d1.htm) |
| [5.1](tm2310003d1_ex5-1.htm) | [Opinion of Goodwin Procter LLP (filed herewith).](tm2310003d1_ex5-1.htm) |
| [23.1](tm2310003d1_ex23-1.htm) | [Consent of KPMG LLP (filed herewith).](tm2310003d1_ex23-1.htm) |
| [23.2](tm2310003d1_ex5-1.htm) | [Consent of Goodwin Procter LLP (included in Exhibit 5.1).](tm2310003d1_ex5-1.htm) |
| [24.1](#v_001) | [Power of Attorney (included in signature page to this Registration Statement).](#v_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1621443/000104746915005872/a2223882zex-10_19a.htm) | [Zynerba Pharmaceuticals, Inc. Amended and Restated 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.19(A) to the Registrant's Registration Statement on Form S-l (File No. 333-205355) filed on June 30, 2015).](https://www.sec.gov/Archives/edgar/data/1621443/000104746915005872/a2223882zex-10_19a.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1621443/000104746915006272/a2225399zex-10_19b.htm) | [Amendment to Amended and Restated 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.19(B) to the Registrant's Amendment No. 1 to Registration Statement on Form S-l (File No. 333-205355) filed on July 23, 2015).](https://www.sec.gov/Archives/edgar/data/1621443/000104746915006272/a2225399zex-10_19b.htm) |
| [107](tm2310003d1_ex-flingfees.htm) | [Filing Fee Table (filed herewith).](tm2310003d1_ex-flingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Devon, Commonwealth of Pennsylvania, on March 28, 2023.

---

| | |
|:---|:---|
| **ZYNERBA PHARMACEUTICALS, INC.** | **ZYNERBA PHARMACEUTICALS, INC.** |
| By: | /s/ Armando Anido |
| Name: | Armando Anido |
| Title: | Chief Executive Officer and Chairman of the Board of Directors |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Armando Anido and James Fickenscher, as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Armando Anido | Chief Executive Officer and Chairman of the Board of Directors | March 28, 2023 |
| Armando Anido | (Principal Executive Officer) |  |
| /s/ James Fickenscher | Chief Financial Officer | March 28, 2023 |
| James Fickenscher | (Principal Financial and Accounting Officer) |  |
| /s/ John Butler | Director | March 28, 2023 |
| John Butler |  |  |
| /s/ Warren D. Cooper | Director | March 28, 2023 |
| Warren D. Cooper |  |  |
| /s/ William J. Federici | Director | March 28, 2023 |
| William J. Federici |  |  |
| /s/ Daniel L. Kisner | Director | March 28, 2023 |
| Daniel L. Kisner |  |  |
| /s/ Kenneth I. Moch | Director | March 28, 2023 |
| Kenneth I. Moch |  |  |
| /s/ Pamela Stephenson | Director | March 28, 2023 |
| Pamela Stephenson |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

March 28, 2023

Zynerba Pharmaceuticals, Inc.

80 W. Lancaster Avenue, Suite 300

Devon, PA 19333

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 1,500,000 shares (the "Shares") of Common Stock, $0.001 par value per share ("Common Stock"), of Zynerba Pharmaceuticals, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the "Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter llp |
| GOODWIN PROCTER LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 28, 2023, with respect to the consolidated financial statements of Zynerba Pharmaceuticals, Inc., incorporated herein by reference.

/s/ KPMG LLP

Philadelphia, Pennsylvania<br> March 28, 2023

## Ex-Filing

**EXHIBIT 107**

**Calculation of Filing Fee Tables**

**Form S-8**<br> (Form Type)

**Zynerba Pharmaceuticals, Inc.**<br> (Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security<br> Class<br> Title** | **Fee<br> Calculation<br> Rule** | **Amount<br> Registered(1)** | **Proposed<br> Maximum<br> Offering Price<br> Per Unit** | **Maximum<br> Aggregate<br> Offering Price** | **Fee Rate** | **Amount of<br> Registration Fee** |
| Fees to Be Paid | Equity | Common<br> Stock, par <br> value <br> $0.001 per <br> share | Rule 457(c) and (h) | 1500000 | $0.43<sup>(2)</sup> | $645000 | 0.0001102 | $71.08 |
|  | **Total Offering Amounts** | **Total Offering Amounts** |  |  |  | $645000 |  | $71.08 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  | – |
|  | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  | – |
|  | **Net Fee Due** |  |  |  |  |  |  | $71.08 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents shares of common stock, $0.001 par value per share, of the Registrant ("Common Stock") that were added to the shares authorized for issuance under the Zynerba Pharmaceuticals, Inc. Amended and Restated 2014 Omnibus Incentive Compensation Plan, as amended (the "Plan"), on January 3, 2023 pursuant to an "evergreen" provision contained in the Plan. Pursuant to such provision, as of the first trading day of January of each year, the number of shares authorized for issuance under the Plan is increased by the lesser of (i) ten percent (10%) of the issued and outstanding shares of Common Stock as of the last trading day in December of the immediately preceding calendar year, or (ii) 1,500,000 shares of Common Stock. Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Common Stock which become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of the Registrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) This estimate is made pursuant to Rule 457(c) and (h) of the Securities Act. The price shown is based upon the average of the high and low prices reported for the Registrant's Common Stock on the Nasdaq Global Market on March 24, 2023.